Latham & Watkins LLP represented Imago BioSciences, Inc. in the offering. Imago BioSciences, Inc. (Imago) (NASDAQ: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP and Wilson Sonsini Goodrich & Rosati represented Erasca in the transaction. Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on...
You must be a Standard 1 Year member to access this content.
Latham & Watkins Advises the Underwriters in the offering while Cooley LLP represented Lyell Immunopharma. Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Janux Therapeutics, Inc. on the deal, while Latham & Watkins LLP represented the underwriters. Janux Therapeutics, Inc., a biopharmaceutical company...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Valo Health on the deal, while Latham & Watkins LLP represented Khosla Ventures Acquisition Co. Valo Health announced its definitive merger agreement with...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP and Wachtell, Lipton, Rosen & Katz represented Ginkgo Bioworks, while White & Case LLP advised Soaring Eagle Acquisition Corp. in the transaction....
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented Treace Medical Concepts, Inc. in the offering. Treace Medical Concepts, Inc. (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented the underwriters in the offering. Rain Therapeutics Inc. (Rain), a clinical-stage company developing precision oncology therapeutics, executed its initial public offering...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented Biomea Fusion, Inc. in the transaction. Biomea Fusion, Inc. (Nasdaq: BMEA) closed its initial public offering of 9 million shares of its...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represents the underwriters in the offering while Wilson Sonsini Goodrich & Rosati advised Reneo Pharmaceuticals, Inc. Reneo Pharmaceuticals, Inc. has announced the pricing...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented the underwriters in the offering while Wilson Sonsini Goodrich & Rosati advised Design Therapeutics, Inc. Design Therapeutics, Inc. executed its initial public...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP and Maples and Calder represented Connect Biopharma in the transaction. Global Law Office and Davis Polk advised joint book-running managers. Connect Biopharma...
You must be a Standard 1 Year member to access this content.
